There remains a need to develop new treatments for pediatric patients with attention deficit/hyperactivity disorder (ADHD), particularly in extended release formulation. One such option might be viloxazine (Qelbree), which gained US Food and Drug Administration approval in April for pediatric ADHD patients between 6-17 years old. (podcast)